1127-P: Real-World Clinical Outcomes Associated with Canagliflozin 100mg and with Intensification of SGLT2 Inhibitor Therapy Switching to Canagliflozin 300mg in Patients with Type 2 Diabetes Mellitus: The Real-WECAN Study

GORGOJO-MARTINEZ, JUAN J. ; GARGALLO-FERNANDEZ, MANUEL A. ; GALDON, ALBA ; ANTÓN-BRAVO, TERESA ; BRITO-SANFIEL, MIGUEL ; WONG-CRUZ, JAIME E.M.

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1) [Periódico revisado por pares]

New York: American Diabetes Association

Texto completo disponível